Cargando…

Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment

INTRODUCTION: Osteoporosis leads to more serious consequences in men than in women, but less is known about its impacts on health-related quality of life (HRQoL) of men, and whether the anti-osteoporosis treatment can improve HRQoL of men with osteopenia/osteoprosis. METHODS: We enrolled men with pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Di-chen, Lin, Xiao-yun, Hu, Jing, Zhou, Bing-na, Zhang, Qian, Wang, Ou, Jiang, Yan, Xia, Wei-bo, Xing, Xiao-ping, Li, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114430/
https://www.ncbi.nlm.nih.gov/pubmed/37076878
http://dx.doi.org/10.1186/s12891-023-06397-8
_version_ 1785028013919830016
author Zhao, Di-chen
Lin, Xiao-yun
Hu, Jing
Zhou, Bing-na
Zhang, Qian
Wang, Ou
Jiang, Yan
Xia, Wei-bo
Xing, Xiao-ping
Li, Mei
author_facet Zhao, Di-chen
Lin, Xiao-yun
Hu, Jing
Zhou, Bing-na
Zhang, Qian
Wang, Ou
Jiang, Yan
Xia, Wei-bo
Xing, Xiao-ping
Li, Mei
author_sort Zhao, Di-chen
collection PubMed
description INTRODUCTION: Osteoporosis leads to more serious consequences in men than in women, but less is known about its impacts on health-related quality of life (HRQoL) of men, and whether the anti-osteoporosis treatment can improve HRQoL of men with osteopenia/osteoprosis. METHODS: We enrolled men with primary osteoporosis and age-matched healthy controls. We collected medical history, serum levels of carboxyl-terminal type I collagen telopeptide, procollagen type I propeptides, and bone mineral density of patients. All patients and controls completed the short-form 36 (SF-36) questionnaires. Changes in HRQoL of osteopenia/osteoporosis men were prospectively evaluated after alendronate or zoledronic acid treatment. RESULTS: A total of 100 men with primary osteoporosis or osteopenia and 100 healthy men were included. The patients were divided into three subgroups: osteopenia (n = 35), osteoporosis (n = 39) and severe osteoporosis (n = 26). Men with osteoporosis or severe osteoporosis had impaired HRQoL in domains of physical health compared to healthy controls. HRQoL scores in physical health related domains of patients with severe osteoporosis were significantly lower compared to healthy controls, and were the poorest among the three subgroups of patients. Fragility fracture history was correlated with lower SF-36 scores about physical health. In 34 men with newly diagnosed osteoporosis receiving bisphosphonates treatment, HRQoL scores were significantly improved in domains of physical health after treatments. CONCLUSIONS: The HRQoL is significantly impaired in men with osteoporosis, and the more severe the osteoporosis, the poorer the HRQoL. Fragility fracture is an important influencing factor of deteriorated HRQoL. Bisphosphonates treatment is beneficial to improve HRQoL of osteopenia/osteoporosis men. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-023-06397-8.
format Online
Article
Text
id pubmed-10114430
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101144302023-04-20 Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment Zhao, Di-chen Lin, Xiao-yun Hu, Jing Zhou, Bing-na Zhang, Qian Wang, Ou Jiang, Yan Xia, Wei-bo Xing, Xiao-ping Li, Mei BMC Musculoskelet Disord Research INTRODUCTION: Osteoporosis leads to more serious consequences in men than in women, but less is known about its impacts on health-related quality of life (HRQoL) of men, and whether the anti-osteoporosis treatment can improve HRQoL of men with osteopenia/osteoprosis. METHODS: We enrolled men with primary osteoporosis and age-matched healthy controls. We collected medical history, serum levels of carboxyl-terminal type I collagen telopeptide, procollagen type I propeptides, and bone mineral density of patients. All patients and controls completed the short-form 36 (SF-36) questionnaires. Changes in HRQoL of osteopenia/osteoporosis men were prospectively evaluated after alendronate or zoledronic acid treatment. RESULTS: A total of 100 men with primary osteoporosis or osteopenia and 100 healthy men were included. The patients were divided into three subgroups: osteopenia (n = 35), osteoporosis (n = 39) and severe osteoporosis (n = 26). Men with osteoporosis or severe osteoporosis had impaired HRQoL in domains of physical health compared to healthy controls. HRQoL scores in physical health related domains of patients with severe osteoporosis were significantly lower compared to healthy controls, and were the poorest among the three subgroups of patients. Fragility fracture history was correlated with lower SF-36 scores about physical health. In 34 men with newly diagnosed osteoporosis receiving bisphosphonates treatment, HRQoL scores were significantly improved in domains of physical health after treatments. CONCLUSIONS: The HRQoL is significantly impaired in men with osteoporosis, and the more severe the osteoporosis, the poorer the HRQoL. Fragility fracture is an important influencing factor of deteriorated HRQoL. Bisphosphonates treatment is beneficial to improve HRQoL of osteopenia/osteoporosis men. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-023-06397-8. BioMed Central 2023-04-19 /pmc/articles/PMC10114430/ /pubmed/37076878 http://dx.doi.org/10.1186/s12891-023-06397-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhao, Di-chen
Lin, Xiao-yun
Hu, Jing
Zhou, Bing-na
Zhang, Qian
Wang, Ou
Jiang, Yan
Xia, Wei-bo
Xing, Xiao-ping
Li, Mei
Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
title Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
title_full Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
title_fullStr Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
title_full_unstemmed Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
title_short Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
title_sort health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114430/
https://www.ncbi.nlm.nih.gov/pubmed/37076878
http://dx.doi.org/10.1186/s12891-023-06397-8
work_keys_str_mv AT zhaodichen healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT linxiaoyun healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT hujing healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT zhoubingna healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT zhangqian healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT wangou healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT jiangyan healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT xiaweibo healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT xingxiaoping healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment
AT limei healthrelatedqualityoflifeofmenwithprimaryosteoporosisanditschangesafterbisphosphonatestreatment